|
WO2020249756A1
|
|
Fusion proteins for tuberculosis vaccines
|
|
WO2020201191A1
|
|
Multivalent malaria transmission-blocking vaccines
|
|
WO2019207115A1
|
|
Improved immunoassays
|
|
CN111526886A
|
|
Multigene influenza vaccines
|
|
WO2017220099A1
|
|
Adjuvants with modified drainage properties
|
|
WO2017084671A1
|
|
Skin Testing for tuberculosis in immunocompromised persons
|
|
EP3193924A1
|
|
Alpha-tocopherol-based adjuvanted solvent for dna vaccines
|
|
WO2015161853A1
|
|
New m.tuberculosis vaccines
|
|
EP3084442A1
|
|
Diagnostic reagents for improved in vivo or in vitro cell-mediated immunological diagnosis of tuberculosis
|
|
RU2723046C2
|
|
Chlamydia sp vaccines
|
|
US2015293111A1
|
|
Method of diagnosing galactosemia in neonatal screening
|
|
WO2014071946A1
|
|
Diagnostic pcr primers enabling exhaustive detection of non-human eukaryotic ssu rdna in human clinical samples
|
|
WO2014063704A2
|
|
M. tuberculosis vaccines
|
|
WO2014063703A1
|
|
Monoclonal antibodies
|
|
AU2012244350B2
|
|
Ip-10 based immunological monitoring
|
|
WO2013064147A1
|
|
Genetic variants associated with cerebral malaria
|
|
US2014170182A1
|
|
Production of a cysteine rich protein
|
|
WO2013037371A1
|
|
Genetic variants associated with infantile hypertrophic pyloric stenosis
|
|
EP2729127A2
|
|
Methods for producing liposomes
|
|
AU2012202486A1
|
|
Tuberculosis vaccine and diagnostics based on the Mycobacterium tuberculosis esat-6 gene family
|
